comparemela.com

Page 7 - Chipscreen Biosciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AKESO ANNOUNCED COLLABORATION WITH CHIPSCREEN BIOSCIENCES TO INITIATED A CLINICAL TRIAL OF PD-1/CTLA-4 BI-SPECIFIC ANTIBODY IN COMBINATION WITH CHIAURANIB FOR PD-(L)1 PRETREATED ES-SCLC

HONG KONG, March 1, 2022 /PRNewswire/ Akeso, Inc. (9926.HK) ( Akeso ), a biopharmaceutical company dedicated to the research, development, manu.

United statesChipscreen biosciencesPrnewswire akeso incDrug administration of the united statesNational medical products administrationShanghai stock exchangeShenzhen chipscreen biosciences co ltdNational medical productsDrug administration

Akeso Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evaluate Cadonilimab in Combination with Chiauranib for Extensive-Stage Small-Cell Lung Cancer

HONG KONG, March 2, 2022 /PRNewswire/ Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the research, development, manufacturing and.

Chipscreen biosciencesShenzhen chipscreen biosciences ltdAkeso incShenzhen chipscreen biosciences

AKESO ANNOUNCED COLLABORATION WITH CHIPSCREEN BIOSCIENCES TO INITIATED A CLINICAL TRIAL OF PD-1/CTLA-4 BI-SPECIFIC ANTIBODY IN COMBINATION WITH CHIAURANIB FOR PD-(L)1 PRETREATED ES-SCLC

/PRNewswire/ Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new.

United statesChipscreen biosciencesPrnewswire akeso incDrug administration of the united statesNational medical products administrationShanghai stock exchangeShenzhen chipscreen biosciences co ltdNational medical productsDrug administration

Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients

/PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1.

Hong kongJun chenJinzij wuChipscreen biosciencesLu xianpingShanghai public health clinical centerAscletis bioscience co ltdHong kong stock exchangeAscletis pharma incPrnewswire ascletis pharma incShenzhen chipscreen biosciences co ltdDeputy chief physicianGeneral managerHepatitisb virusPrimary biliary cholangitisAscletis pharma inc

Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients

HANGZHOU, China and SHAOXING, China, Feb. 14, 2022 /PRNewswire/ Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide in patients infected by human immunodeficiency virus (HIV) with antiviral suppression. The objective of this study (ClinicalTrials.gov Identifier: NCT05129189) is to evaluate the.

Hong kongJun chenJinzij wuChipscreen biosciencesLu xianpingShanghai public health clinical centerAscletis bioscience co ltdHong kong stock exchangePrnewswire ascletis pharma incShenzhen chipscreen biosciences co ltdDeputy chief physicianGeneral managerHepatitisb virusPrimary biliary cholangitis

vimarsana © 2020. All Rights Reserved.